Acrivon Therapeutics

Acrivon's Predictive Precision Proteomics (AP3) platform directly measures drug-induced protein phosphorylation signaling in live tumor tissue, rather than inferring drug sensitivity from DNA mutations alone. The technology captures real-time functional responses of cancer pathways — a method Blume-Jensen and collaborators pioneered at Merck and Massachusetts General Hospital — and uses a machine-learning algorithm to predict patient response. This allows the firm to select patients for clinical trials based on a functional, dynamic biomarker rather than a static genetic one (per the firm's SEC filings).

ACR-368, a CHK1/2 inhibitor, is in a registrational Phase 2b clinical trial for patients with platinum-resistant ovarian and endometrial cancer, with enrollment ongoing as of 2024. The trial is designed to support accelerated approval, and the company has guided for a partial clinical data readout in the second half of 2025. This single study is intended to serve as the basis for a New Drug Application filing, provided it meets its primary endpoint of objective response rate in the selected population (per clinicaltrials.gov).

No. Acrivon is a clinical-stage biotechnology company and does not generate revenue from commercial product sales. Its funding has come from venture capital — notably RA Capital and Perceptive Advisors — and a $120 million initial public offering in 2022. The firm's operational runway is dependent on equity capital markets and potential future partnership milestones, not recurring cash flow.

Acrivon was co-founded with roots at the Karolinska Institute in Stockholm, where some foundational work on the AP3 phosphoproteomics platform was developed. The company maintains a research laboratory and subsidiary in Sweden, which handles the high-throughput proteomics processing of patient tumor samples collected from its clinical trials. The US headquarters in Watertown houses executive leadership, clinical operations, and the translational science team.

Acrivon's disclosed pipeline includes only two wholly owned programs: ACR-368, its CHK1/2 inhibitor, and ACR-2316, a WEE1 kinase inhibitor that entered clinical development in 2023 with a Phase 1 trial. The WEE1 program is designed to overcome the severe bone-marrow toxicity that has limited a competing drug from AstraZeneca, giving Acrivon a potential best-in-class window. The company's strategy is to build a pipeline of DNA damage repair inhibitors, with earlier-stage, undisclosed programs underpinned by the AP3 platform.

The firm was founded by CEO Peter Blume-Jensen, who previously led oncology therapy-area research at Merck and held academic posts at Massachusetts General Hospital and Harvard Medical School. Co-founders include Professor Thomas Helleday of the Karolinska Institute, a DNA repair biology expert, and Professor Michael Yaffe of MIT and Beth Israel Deaconess Medical Center, a phosphoproteomics and systems biology specialist. This trio's combined expertise forms the company's foundational intellectual property.

Acrivon Therapeutics is a clinical-stage, publicly traded oncology drug-development company, not an investment vehicle or family office. It is listed on the Nasdaq exchange under the ticker ACRV. Its business is conducting clinical trials and developing pharmaceutical assets, with no function as a capital allocator to external funds or companies.